Literature DB >> 3580139

Dose-dependent suppression of the high alcohol intake of chronically intoxicated rats by Ca-acetyl homotaurinate.

J Le Magnen, G Tran, J Durlach, C Martin.   

Abstract

The effect of taurine derivative, Ca-acetyl homotaurinate, on voluntary alcohol intake was investigated in ethanol-dependent and naive rats. A high 24 hr oral intake of a 10% ethyl alcohol solution (9-10 g/kg) was exhibited by rats following 15 days of intragastric infusions of ethanol (7-8 g/kg/day). In four groups, rats were IG injected by short pulses of isotonic saline or a daily dose of 200, 300 and 450 mg/kg respectively, distributed over six daily infusions during alternating 8 hr presentations of ethanol solution and water. Compared to their respective basal intakes during the first two days of injection, the rats demonstrated a dose-dependent 50 to 70% reduction in alcohol consumption with drug treatment. This suppression effect was specific to the ethanol solution and persisted during 4 days of post-treatment observation. In ethanol-naive rats similarly tested and drinking half the amount of alcohol drunk by their ethanol-dependent counterparts, only the highest dose of drug (450 mg/kg) significantly suppressed their alcohol intake. It is suggested that Ca-acetyl homotaurinate interacts with CNS mechanisms involved in the ethanol tolerance-dependence state, underlying an enhanced reinforcing property of ethanol oral intake. Opioid receptors could be the targets in this action.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3580139     DOI: 10.1016/0741-8329(87)90005-x

Source DB:  PubMed          Journal:  Alcohol        ISSN: 0741-8329            Impact factor:   2.405


  16 in total

Review 1.  Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

Authors:  George F Koob
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

Review 2.  The development of acamprosate as a treatment against alcohol relapse.

Authors:  Peter R Kufahl; Lucas R Watterson; M Foster Olive
Journal:  Expert Opin Drug Discov       Date:  2014-09-26       Impact factor: 6.098

Review 3.  Building better strategies to develop new medications in Alcohol Use Disorder: Learning from past success and failure to shape a brighter future.

Authors:  Nazzareno Cannella; Massimo Ubaldi; Alessio Masi; Massimo Bramucci; Marisa Roberto; Angelo Bifone; Roberto Ciccocioppo
Journal:  Neurosci Biobehav Rev       Date:  2019-05-18       Impact factor: 8.989

Review 4.  Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification.

Authors:  M I Wilde; A J Wagstaff
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

5.  Comparison of dehydroepiandrosterone (DHEA) and pregnanolone with existing pharmacotherapies for alcohol abuse on ethanol- and food-maintained responding in male rats.

Authors:  Mary W Hulin; Michelle N Lawrence; Russell J Amato; Peter F Weed; Peter J Winsauer
Journal:  Alcohol       Date:  2015-01-06       Impact factor: 2.405

Review 6.  The clinical pharmacology of acamprosate.

Authors:  Nicola J Kalk; Anne R Lingford-Hughes
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 7.  Acamprosate: a review of its use in the maintenance of abstinence in patients with alcohol dependence.

Authors:  Lesley J Scott; David P Figgitt; Susan J Keam; John Waugh
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

8.  Acamprosate attenuates cocaine- and cue-induced reinstatement of cocaine-seeking behavior in rats.

Authors:  M Scott Bowers; Billy T Chen; Jonathan K Chou; Megan P H Osborne; Justin T Gass; Ronald E See; Antonello Bonci; Patricia H Janak; M Foster Olive
Journal:  Psychopharmacology (Berl)       Date:  2007-09-02       Impact factor: 4.530

Review 9.  Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities.

Authors:  M Soyka
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

Review 10.  Clinical pharmacokinetics of acamprosate.

Authors:  S Saivin; T Hulot; S Chabac; A Potgieter; P Durbin; G Houin
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.